About

About CdmoGen A one-stop CTDMO, CdmoGen Co., Ltd. offers comprehensive and integrated contract services spanning the full length of the cell and gene therapy development process. From early optimization to the GMP and non-GMP manufacture of virus vector- and mRNA-based therapeutics, through CMC support and a robust panel of quality analyses, including lot release testing, CdmoGen is a full-service partner providing reliable and efficient developmental support. Recognized as the first GMP-compliant manufacturer approved by the Ministry of Food and Drug Safety (Republic of Korea), CdmoGen is also ISO17025-accredited, and has successfully completed over 250 GMP manufacturing and QC testing projects involving virus vector-based gene therapeutics and vaccines since 2016. In addition to continually working to increase its custom service capabilities, including validation studies and process, assay, and SOP development, CdmoGen brought online in 2023 a custom-built facility dedicated to the manufacture and testing of mRNA vaccines to further expand its service offerings. Virus seed stock and cell banking will also take place in this facility. Since its inception, CdmoGen has, through its experiences, expanded its knowledge base while establishing a track record for success, with a CTDMO customer having recently been approved for a clinical trial by the FDA. Moving forward, CdmoGen will do all it can to provide every partner with the support they need to achieve their own successes in the development of biopharmaceuticals and cell and gene therapeutics. About CdmoGen Co., Ltd. A one-stop CTDMO, CdmoGen Co., Ltd. offers comprehensive and integrated contract services spanning the full length of the cell and gene therapy development process. From early optimization to the GMP and non-GMP manufacture of virus vector- and mRNA-based therapeutics, through CMC support and a robust panel of quality analyses, including lot release testing, CdmoGen is a full-service partner providing reliable and efficient developmental support. Recognized as the first GMP-compliant manufacturer approved by the Ministry of Food and Drug Safety (Republic of Korea), CdmoGen is also ISO17025-accredited, and has successfully completed over 250 GMP manufacturing and QC testing projects involving virus vector-based gene therapeutics and vaccines since 2016. In addition to continually working to increase its custom service capabilities, including validation studies and process, assay, and SOP development, CdmoGen brought online in 2023 a custom-built facility dedicated to the manufacture and testing of mRNA vaccines to further expand its service offerings. Virus seed stock and cell banking will also take place in this facility. Since its inception, CdmoGen has, through its experiences, expanded its knowledge base while establishing a track record for success, with a CTDMO customer having recently been approved for a clinical trial by the FDA. Moving forward, CdmoGen will do all it can to provide every partner with the support they need to achieve their own successes in the development of biopharmaceuticals and cell and gene therapeutics. CdmoGen Co., Ltd. is a gene therapy new drug development company specializing in therapeutics for ocular diseases that also offers one-stop, full-service CTDMO services for virus vector- and mRNA technology-based biopharmaceuticals.